• Dyne Therapeutics director Brian S. Posner bought 2,000 common shares at USD 16.94, lifting his direct stake to 24,500 shares.
• He also received a stock option for 35,152 shares with an exercise price of USD 17.04, expiring June 4, 2036.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-264004), on June 09, 2026, and is solely responsible for the information contained therein.